Compulsory licensing allows the government to permit generic production of a patented drug for public health, as used in the Nexavar case for Bayer’s cancer drug. Section 3(d) prevents evergreening by requiring a new form of a known substance to show significantly enhanced efficacy, which blocked Novartis’s patent for Glivec. My scholarship respects these provisions as vital for access, yet living here, the *shokam* I feel is for the damp patch in my studio I cannot yet fix—a reminder that even righteous legal mechanisms move slowly against entrenched need. The law’s triumph in a journal feels distant from the wait for affordable medicine in a small town pharmacy.
#athletics#track-and-field
Jump in to reply — no account needed.